Protein farnesyltransferase: Flexible docking studies on inhibitors using computational modeling

Wayne C. Guida, Andrew Hamilton, Justin W. Crotty, Saïd M. Sebti

Research output: Contribution to journalArticle

Abstract

Using MacroModel, peptide, peptidomimetic and non-peptidomimetic inhibitors of the zinc metalloenzyme, farnesyltransferase (FTase), were docked into the enzyme binding site. Inhibitor flexibility, farnesyl pyrophosphate substrate flexibility, and partial protein flexibility were taken into account in these docking studies. In addition to CVFM and CVIM, as well as our own inhibitors FTI-276 and FTI-2148, we have docked other farnesyltransferase inhibitors (FTIs) including Zarnestra, which presently is in advanced clinical trials. The AMBER*force field was employed, augmented with parameters that were derived for zinc. A single binding site model that was derived from the crystal structure of CVFM complexed with farnesyltransferase and farnesylpyrophosphate was used for these studies. The docking results using the lowest energy structure from the simulation, or one of the lowest energy structures, were generally in excellent agreement with the X-ray structures. One of the most important findings of this study is that numerous alternative conformations for the methionine side chain can be accommodated by the enzyme suggesting that the methionine pocket can tolerate groups larger than methionine at the C-terminus of the tetrapeptide and suggesting alternative locations for the placement of side chains that may improve potency.

Original languageEnglish (US)
Pages (from-to)871-885
Number of pages15
JournalJournal of Computer-Aided Molecular Design
Volume19
Issue number12
DOIs
StatePublished - Dec 2005

Fingerprint

Farnesyltranstransferase
Binding sites
inhibitors
Zinc
Enzymes
proteins
Proteins
methionine
Methionine
Peptides
Conformations
flexibility
Crystal structure
tipifarnib
X rays
Binding Sites
enzymes
Peptidomimetics
Substrates
zinc

Keywords

  • Docking
  • Drug design
  • Flexible docking
  • Molecular modeling
  • Protein farnesyltransferase

ASJC Scopus subject areas

  • Molecular Medicine

Cite this

Protein farnesyltransferase : Flexible docking studies on inhibitors using computational modeling. / Guida, Wayne C.; Hamilton, Andrew; Crotty, Justin W.; Sebti, Saïd M.

In: Journal of Computer-Aided Molecular Design, Vol. 19, No. 12, 12.2005, p. 871-885.

Research output: Contribution to journalArticle

@article{7097faedf4dc40e3b25444c0615167b1,
title = "Protein farnesyltransferase: Flexible docking studies on inhibitors using computational modeling",
abstract = "Using MacroModel, peptide, peptidomimetic and non-peptidomimetic inhibitors of the zinc metalloenzyme, farnesyltransferase (FTase), were docked into the enzyme binding site. Inhibitor flexibility, farnesyl pyrophosphate substrate flexibility, and partial protein flexibility were taken into account in these docking studies. In addition to CVFM and CVIM, as well as our own inhibitors FTI-276 and FTI-2148, we have docked other farnesyltransferase inhibitors (FTIs) including Zarnestra, which presently is in advanced clinical trials. The AMBER*force field was employed, augmented with parameters that were derived for zinc. A single binding site model that was derived from the crystal structure of CVFM complexed with farnesyltransferase and farnesylpyrophosphate was used for these studies. The docking results using the lowest energy structure from the simulation, or one of the lowest energy structures, were generally in excellent agreement with the X-ray structures. One of the most important findings of this study is that numerous alternative conformations for the methionine side chain can be accommodated by the enzyme suggesting that the methionine pocket can tolerate groups larger than methionine at the C-terminus of the tetrapeptide and suggesting alternative locations for the placement of side chains that may improve potency.",
keywords = "Docking, Drug design, Flexible docking, Molecular modeling, Protein farnesyltransferase",
author = "Guida, {Wayne C.} and Andrew Hamilton and Crotty, {Justin W.} and Sebti, {Sa{\"i}d M.}",
year = "2005",
month = "12",
doi = "10.1007/s10822-005-9030-2",
language = "English (US)",
volume = "19",
pages = "871--885",
journal = "Journal of Computer-Aided Molecular Design",
issn = "0920-654X",
publisher = "Springer Netherlands",
number = "12",

}

TY - JOUR

T1 - Protein farnesyltransferase

T2 - Flexible docking studies on inhibitors using computational modeling

AU - Guida, Wayne C.

AU - Hamilton, Andrew

AU - Crotty, Justin W.

AU - Sebti, Saïd M.

PY - 2005/12

Y1 - 2005/12

N2 - Using MacroModel, peptide, peptidomimetic and non-peptidomimetic inhibitors of the zinc metalloenzyme, farnesyltransferase (FTase), were docked into the enzyme binding site. Inhibitor flexibility, farnesyl pyrophosphate substrate flexibility, and partial protein flexibility were taken into account in these docking studies. In addition to CVFM and CVIM, as well as our own inhibitors FTI-276 and FTI-2148, we have docked other farnesyltransferase inhibitors (FTIs) including Zarnestra, which presently is in advanced clinical trials. The AMBER*force field was employed, augmented with parameters that were derived for zinc. A single binding site model that was derived from the crystal structure of CVFM complexed with farnesyltransferase and farnesylpyrophosphate was used for these studies. The docking results using the lowest energy structure from the simulation, or one of the lowest energy structures, were generally in excellent agreement with the X-ray structures. One of the most important findings of this study is that numerous alternative conformations for the methionine side chain can be accommodated by the enzyme suggesting that the methionine pocket can tolerate groups larger than methionine at the C-terminus of the tetrapeptide and suggesting alternative locations for the placement of side chains that may improve potency.

AB - Using MacroModel, peptide, peptidomimetic and non-peptidomimetic inhibitors of the zinc metalloenzyme, farnesyltransferase (FTase), were docked into the enzyme binding site. Inhibitor flexibility, farnesyl pyrophosphate substrate flexibility, and partial protein flexibility were taken into account in these docking studies. In addition to CVFM and CVIM, as well as our own inhibitors FTI-276 and FTI-2148, we have docked other farnesyltransferase inhibitors (FTIs) including Zarnestra, which presently is in advanced clinical trials. The AMBER*force field was employed, augmented with parameters that were derived for zinc. A single binding site model that was derived from the crystal structure of CVFM complexed with farnesyltransferase and farnesylpyrophosphate was used for these studies. The docking results using the lowest energy structure from the simulation, or one of the lowest energy structures, were generally in excellent agreement with the X-ray structures. One of the most important findings of this study is that numerous alternative conformations for the methionine side chain can be accommodated by the enzyme suggesting that the methionine pocket can tolerate groups larger than methionine at the C-terminus of the tetrapeptide and suggesting alternative locations for the placement of side chains that may improve potency.

KW - Docking

KW - Drug design

KW - Flexible docking

KW - Molecular modeling

KW - Protein farnesyltransferase

UR - http://www.scopus.com/inward/record.url?scp=33744947824&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33744947824&partnerID=8YFLogxK

U2 - 10.1007/s10822-005-9030-2

DO - 10.1007/s10822-005-9030-2

M3 - Article

VL - 19

SP - 871

EP - 885

JO - Journal of Computer-Aided Molecular Design

JF - Journal of Computer-Aided Molecular Design

SN - 0920-654X

IS - 12

ER -